BioNTech SE, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $140.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors that highlight BioNTech SE’s promising clinical trial results. The company’s Phase 2 trial results for the combination of pumitamig and chemotherapy in treating triple-negative breast cancer (TNBC) patients showed a high overall response rate (ORR) of 72%, which is consistent with previous studies. This consistency in results suggests a strong potential for success in the ongoing Phase 3 Rosetta Breast-01 trial, reducing the risk associated with the trial’s outcome.
Additionally, BioNTech’s Phase 3 PRESERVE-003 trial results for gotistobart, an anti-CTLA4 monoclonal antibody, demonstrated a significant reduction in the risk of death by 54% in patients with squamous non-small cell lung cancer (NSCLC) who had previously undergone anti-PD-(L)1 therapy. These encouraging results, presented at a major conference, further support the potential efficacy of BioNTech’s treatments, reinforcing the Buy rating given by Robert Burns.
In another report released today, Clear Street also maintained a Buy rating on the stock with a $181.00 price target.